Abstract
Radiation esophagitis is an acute dose-limiting toxicity associated with radiation treatment that decreases the patient’s compliance for treatment completion.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Le Chevalier T, Arriagada R, Quoix E, Ruffle P, Martin M, Tarayre M et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83(6):417–423
Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R (2006) Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66(1):100–107
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323(14):940–945
Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al (2011) Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized Phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460
Squier CA, Kremer MJ (2000) Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 29:7–15
Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y (eds) (1999) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9(2 Suppl 1):90–96
Ozgen A, Hayran M, Kahraman F (2012) Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung cancer patients treated with concurrent radiotherapy and chemotherapy. J Radiat Res 53(6):916–922
Ball D, Bishop J, Smith J, Crennan E, O’Brien P, Davis S et al (1995) A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 31(2):267–272
Bradley J, Deasy JO, Bentzen S, El Naqa I (2004) Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58(4):1106–1113
Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T et al (1998) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16(10):3316–3322
Qiao W-B, Zhao Y-H, Zhao Y-B, Wang R-Z (2005) Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity. World J Gastroenterol 11(17):2626–2629
Maguire PD, Sibley GS, Zhou S-M, Jamieson TA, Light KL, Antoine PA et al (1999) Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45(1):97–103
Singh AK, Lockett MA, Bradley JD (2003) Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 55(2):337–341
Byhardt R, Scott C, Sause W, Emami B, Komaki R, Fisher B et al (1998) Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42(3):469–478
Werner-Wasik M, Pequignot E, Leeper D, Hauck W, Curran W (2000) Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 48(3):689–696
Werner-Wasik M, Paulus R, Curran WJ, Byhardt R (2011) Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 12(4):245–251
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340(4):265–271
Werner-Wasik M, Scott C, Graham ML, Smith C, Byhardt RW, Roach M et al (1999) Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys 44(2):327–331
Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 75(2):157–164
Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC et al (2003) Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21(9):1767–1774
Maraz A, Furak J, Varga Z, Fodor E, Egyued Z, BorzĂ¡si E et al (2013) Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer. Anticancer Res 33(4):1737–1741
Bar-Ad V, Leiby B, Witek M, Xiao Y, Cui Y, Dai Y et al (2014) Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy. Am J Clin Oncol 37(5):433–437
Takeda K, Nemoto K, Saito H, Ogawa Y, Takai Y, Yamada S (2006) Predictive factors for acute esophageal toxicity in thoracic radiotherapy. Tohoku J Exp Med 208(4):299–306
Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA et al (2009) Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 74(4):1108–1113
Zehentmayr F, Söhn M, Exeli A-K, Wurstbauer K, Tröller A, Deutschmann H et al (2015) Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid). Radiat Oncol 10(1):121
RodrĂguez N, Algara M, Foro P, Lacruz M, Reig A, Membrive I et al (2009) Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 73(3):810–817
Zhang Z, Xu J, Zhou T, Yi Y, Li H, Sun H et al (2014) Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy. Radiat Oncol 9(1):54
Kuroda Y, Sekine I, Sumi M, Sekii S, Takahashi K, Inaba K et al (2013) Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer. Technol Cancer Res Treat 12(4):333–339
Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD et al (2013) Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 87(4):690–696
Patel AB, Edelman MJ, Kwok Y, Krasna MJ, Suntharalingam M (2004) Predictors of acute esophagitis in patients with non-small cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60(4):1106–1112
Huang EX, Bradley JD, El Naqa I, Hope AJ, Lindsay PE, Bosch WR et al (2012) Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients. Int J Radiat Oncol Biol Phys 82(5):1674–1679
Gong B, Jiang N, Yan G, Wang S, Deng C, Wei S et al (2016) Predictors for severe acute esophagitis in lung cancer patients treated with chemoradiotherapy: a systematic review. Curr Med Res Opin 32(10):1701–1708
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D et al (eds) (1997) Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol 24(4 Suppl 12):S12-89–S12-95
Yu Y, Guan H, Dong Y, Xing L, Li X (2016) Advances in dosimetry and biological predictors of radiation-induced esophagitis. Onco Targets Ther 9:597–603
Ellingrod VL, Schipper M, Stringer KA, Cai X, Hayman JA, Yu J et al (2013) Genetic variations in TGFβ1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer. J Thorac Oncol 8(2):208–213
Guerra JLL, Wei Q, Yuan X, Gomez D, Liu Z, Zhuang Y et al (2011) Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio (chemo) therapy. Radiother Oncol 101(2):271–277
Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y et al (2010) Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 5(8):e12402
Everitt S, Duffy M, Bressel M, McInnes B, Russell C, Sevitt T et al (2016) Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer. Radiat Oncol 11(1):20
Tang C, Liao Z, Zhuang Y, Levy LB, Hung C, Li X et al (2014) Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol 110(3):493–498
Leigh BR, Lau DH (1998) Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature. Am J Clin Oncol 21(5):479–481
Costleigh BJ, Miyamoto CT, Micaily B, Brady LW (1995) Heightened sensitivity of the esophagus to radiation in a patient with AIDS. Am J Gastroenterol 90(5):812–814
Chapet O, Kong F-M, Lee JS, Hayman JA, Ten Haken RK (2005) Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 77(2):176–181
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346
Nijkamp J, Rossi M, Lebesque J, Belderbos J, van den Heuvel M, Kwint M et al (2013) Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 106(1):118–123
Yuan ST, Brown RK, Zhao L, Ten Haken RK, Gross M, Cease KB et al (2014) Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiat Oncol 9(1):37
Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke J-J et al (2012) Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 84(2):e223–e228
Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12(6):738–747
Antonadou D, Coliarakis N, Synodinou M, Athanassiou H, Kouveli A, Verigos C et al (2001) Randomized phase III trial of radiation treatment±amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51(4):915–922
Komaki R, Lee J, Kaplan B, Allen P, Kelly J, Liao Z et al (eds) (2002) Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12:46–49
Lawrence YR, Paulus R, Langer C, Werner-Wasik M, Buyyounouski MK, Komaki R et al (2013) The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 80(3):298–305
Werner-Wasik M, Axelrod RS, Friedland DP, Hauck W, Rose LJ, Chapman AE et al (eds) (2002) Phase II: Trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Semin Radiat Oncol 12:34–39
Topkan E, Yavuz MN, Onal C, Yavuz AA (2009) Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. Lung Cancer 63(3):393–399
McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR et al (1997) Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol 15(3):1239–1243
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Sourati, A., Ameri, A., Malekzadeh, M. (2017). Esophagitis. In: Acute Side Effects of Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-55950-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-55950-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55949-0
Online ISBN: 978-3-319-55950-6
eBook Packages: MedicineMedicine (R0)